Emerging Biomarkers and Therapeutic Targets in Cancer Immunotherapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 1390

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warszawa, Poland
Interests: carotid plaques; atherosclerotic plaque; checkpoint inhibitors; exosomes; cancer immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite the successes in cancer management, some immunotherapies can dysregulate the immune system, leading to immune-mediated adverse events. Extracellular vesicles (Evs), including exosomes, are emerging as key players in tumor immunology. Importantly, tumor-derived EVs (TDEs) contain a unique molecular signature that is reflective of the tumor's underlying genetic complexity. They offer a glimpse into the immune tumor microenvironment (TME) and have the potential to be a novel, minimally invasive biomarker for cancer immunotherapy. Immune checkpoint inhibitors (ICI), such as anti-programmed death-1(PD-1), its ligand (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)- antibodies, have revolutionized the treatment of a wide variety of tumors. Despite the success of many cancer immunotherapies, such as CAR-T therapy, there is still a need for noninvasive or minimally invasive biomarkers both for diagnosis and treatment monitoring. The targeted analysis of markers in biospecimens such as plasma could serve this purpose by potentially obviating the need for a tissue sample. Therefore the purpose of this Special Issue is analyze the current challenges in the selection of biomarkers and therapeutic targets in cancer immunotherapy to modulate the antitumor immune response.

Dr. Wioletta Olejarz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immonotherapy
  • CAR-T therapy
  • biomarkers
  • immune checkpoint inhibitors
  • extracellular vesicles
  • exosomes
  • drug resistance
  • drug discovery
  • therapeutic regimens

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 2050 KiB  
Review
Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies
by Wioletta Olejarz and Grzegorz Basak
Cancers 2023, 15(24), 5765; https://doi.org/10.3390/cancers15245765 - 8 Dec 2023
Viewed by 1117
Abstract
CAR-T cell therapy has revolutionized the treatment of hematological malignancies with high remission rates in the case of ALL and NHL. This therapy has some limitations such as long manufacturing periods, persistent restricted cell sources and high costs. Moreover, combination regimens increase the [...] Read more.
CAR-T cell therapy has revolutionized the treatment of hematological malignancies with high remission rates in the case of ALL and NHL. This therapy has some limitations such as long manufacturing periods, persistent restricted cell sources and high costs. Moreover, combination regimens increase the risk of immune-related adverse events, so the identification new therapeutic targets is important to minimize the risk of toxicities and to guide more effective approaches. Cancer cells employ several mechanisms to evade immunosurveillance, which causes resistance to immunotherapy; therefore, a very important therapeutic approach is to focus on the development of rational combinations of targeted therapies with non-overlapping toxicities. Recent progress in the development of new inhibitory clusters of differentiation (CDs), signaling pathway molecules, checkpoint inhibitors, and immunosuppressive cell subsets and factors in the tumor microenvironment (TME) has significantly improved anticancer responses. Novel strategies regarding combination immunotherapies with CAR-T cells are the most promising approach to cure cancer. Full article
(This article belongs to the Special Issue Emerging Biomarkers and Therapeutic Targets in Cancer Immunotherapy)
Show Figures

Figure 1

Back to TopTop